Esperion Therapeutics, Inc. Merger Agreement Update

This Form 8-K filing by Esperion Therapeutics, Inc. provides an update on their Agreement and Plan of Merger with Essence Parent Inc. The Hart-Scott-Rodino antitrust waiting period expired on June 15, 2026, clearing a significant hurdle for the merger. The completion of the merger is still subject to other customary closing conditions, including adoption by Esperion’s stockholders at a special meeting scheduled for July 8, 2026. The filing also includes forward-looking statements regarding the acquisition and potential risks, as well as information on where to find additional details about the transaction, including the proxy statement filed with the SEC.